{
    "clinical_study": {
        "@rank": "149815", 
        "arm_group": [
            {
                "arm_group_label": "LY03004", 
                "arm_group_type": "Experimental", 
                "description": "5 intramuscular injections 25 mg over 113 days"
            }, 
            {
                "arm_group_label": "Risperdal\u00ae Consta\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "5 intramuscular injections 25 mg over 113 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to assess the bioavailability of LY03004  compared to Risperdal Consta as well\n      as the evaluate the safety and tolerability and preliminary efficacy of LY03004 with repeat\n      injections"
        }, 
        "brief_title": "Bioavailability of LY03004 and Risperdal\u00ae Consta\u00ae", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Schizophrenia", 
            "Schizoaffective Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Psychotic Disorders", 
                "Schizophrenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  To assess the relative bioavailability of LY03004 compared to Risperdal\u00ae Consta\u00ae at 25\n           mg following multiple intramuscular injections at steady-state;\n\n        -  To evaluate the safety and tolerability of LY03004 following repeated intramuscular\n           injections\n\n        -  To evaluate the preliminary efficacy of LY03004 following repeated intramuscular\n           injections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female patients aged 18 to 65 years old\n\n          2. Patients must have a DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder\n             based on the Mini-International Neuropsychiatric Interview (MINI)\n\n          3. Patients must be clinically stable on antipsychotic medications other than\n             risperidone or paliperidone or clozapine for at least 4 weeks prior to screening,\n             based on clinical assessments AND a Positive and Negative Syndrome Scale (PANSS)\n             total score less than or equal 70 at Screening Visit\n\n          4. Patients with a Body Mass Index in range of 18.0 to 35.0\n\n          5. Patients with an Informed Consent Form signed by the patient or legally authorized\n             representative\n\n        Exclusion Criteria:\n\n          1. Patients with a mental disorders other than schizophrenia or schizoaffective\n             disorder, according to the DSM-IV-TR\n\n          2. Patients who received oral risperidone or paliperidone or clozapine within 14 days\n             prior to screening, or Risperdal\u00ae Consta\u00ae within 100 days prior to screening or\n             paliperidone palmitate within 10 months prior to screening\n\n          3. Patients with neuroleptic malignant syndrome or physical fatigue associated with\n             dehydration or malnutrition\n\n          4. Patients who pose a significant risk of a suicide attempt based on history,\n             investigator's judgment or have answered \"yes\" to the questions 4 or 5 for current or\n             past 30 days on the screening form of the Columbia Suicide Severity Rating Scale\n             (C-SSRS)\n\n          5. Patients with a history of sensitivity to akathisia and other EPS, especially with\n             previous use of risperidone or paliperidone\n\n          6. Patients with uncontrolled diabetes mellitus as indicated by a HbA1c level greater\n             than or equal to 7%\n\n          7. Patients with a history of or currently having epilepsy or convulsion disorders\n\n          8. Patients who have had electroconvulsive therapy within the past 2 months prior to\n             screening\n\n          9. Patients who used medication known to be an inducer or inhibitor for CYP 2D6 within 2\n             weeks prior to screening\n\n         10. Patients with a history of allergic reaction to risperidone or to the excipients of\n             LY03004\n\n         11. Patients who have met DSM-IV-TR criteria for substance abuse or dependence with the\n             exception of caffeine or nicotine in the past 6 months prior to screening\n\n         12. Patients with a history of clinically relevant cardiac arrhythmia's, cardiovascular\n             disease, thyrotoxicosis, parkinsonism, or hemorrhagic diathesis\n\n         13. Patients who are currently taking medications with primarily CNS activities such as\n             antidepressants, mood stabilizers or anticonvulsants\n\n         14. Patients who have participated in a clinical trial of another investigational drug\n             within 30 days prior to screening\n\n         15. Female patients who are pregnant or are breastfeeding or are of childbearing\n             potential without adequate use of contraception\n\n         16. Patients who have any clinically relevant hepatic, renal and cardiac dysfunction, or\n             other medical condition or laboratory abnormality, which in the judgment of the\n             investigator would interfere with the subject's ability to participate in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091388", 
            "org_study_id": "LY03004 MD"
        }, 
        "intervention": [
            {
                "arm_group_label": "LY03004", 
                "intervention_name": "LY03004", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Risperdal\u00ae Consta\u00ae", 
                "intervention_name": "Risperdal\u00ae Consta\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Risperidone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 18, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal\u00ae Consta\u00ae at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder", 
        "overall_contact": {
            "email": "simonli@luye.cn", 
            "last_name": "Simon Li"
        }, 
        "overall_official": {
            "affiliation": "Luye Pharma Group Ltd.", 
            "last_name": "Simon Li", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Cmax, Tmax, for Relative bioavailability of LY03004 compared to Risperdal\u00ae Consta\u00ae", 
            "safety_issue": "No", 
            "time_frame": "113 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091388"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "113 Days"
            }, 
            {
                "measure": "The change of the PANSS score for the Preliminary efficacy of LY03004", 
                "safety_issue": "No", 
                "time_frame": "113 Days"
            }
        ], 
        "source": "Luye Pharma Group Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Luye Pharma Group Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}